Gingival Crevicular Fluid Oxidized Low-Density Lipoprotein Levels in Health and Stage III/IV Periodontitis (LDL in GCF)

September 2, 2025 updated by: shaimaa hamdy

Gingival Crevicular Fluid Oxidized Low-Density Lipoprotein Levels in Health and Stage III/IV Periodontitis: A Cross-Sectional Comparative Study

Periodontitis is a chronic, multifactorial inflammatory disease primarily caused by dysbiotic plaque biofilms, characterized by the progressive destruction of the supporting structures of the teeth. In advanced stages (Stage III/IV), periodontitis leads to significant attachment and bone loss, often culminating in tooth loss and a negative impact on the patient's quality of life. Recent evidence has emphasized the systemic implications of periodontal inflammation, suggesting a bidirectional relationship between periodontitis and various systemic conditions, especially cardiovascular diseases

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Oxidative stress has emerged as a key pathogenic mechanism linking periodontal inflammation with systemic diseases. Among the oxidative stress-related biomarkers, oxidized low-density lipoprotein (oxLDL) has gained attention due to its pro-inflammatory, atherogenic, and cytotoxic properties. oxLDL is known to accumulate in vascular walls and contributes to the initiation and progression of atherosclerosis. Its role in periodontal disease, however, remains less well characterized. Gingival crevicular fluid (GCF) is a non-invasive biological fluid that reflects the inflammatory status of the periodontal tissues. Measuring oxLDL levels in GCF may provide valuable insight into the local oxidative burden associated with periodontal destruction. It may also help elucidate the mechanistic link between periodontal and systemic inflammatory diseases. While several studies have investigated oxLDL levels in serum in patients with periodontitis, only limited data exist regarding its levels in GCF, particularly among elderly populations who are more prone to both periodontitis and oxidative stress-related diseases. Understanding these levels could provide novel biomarkers for disease severity and progression, potentially guiding future preventive and therapeutic strategies The detection of elevated oxLDL levels in gingival crevicular fluid (GCF) could therefore serve as a meaningful, site-specific biomarker for disease activity and severity in older populations. Investigating this relationship could enhance our understanding of the oxidative mechanisms underpinning periodontal breakdown and help identify new diagnostic or prognostic markers, particularly in geriatric patients with complex medical profiles Aim of the Study To compare the levels of oxidized low-density lipoprotein (oxLDL) in gingival crevicular fluid (GCF) between healthy individuals and patients with Stage III/IV periodontitis.

Study Type

Observational

Enrollment (Estimated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

cross sectional study in upper egypt to detect the level of LDL in advanced periodontitis patient

Description

Inclusion Criteria:

  • For all participants (applies to both groups):

    1. Age 30-60 years.
    2. Systemically healthy (based on medical history and physician clearance, if needed).
    3. No history of periodontal treatment within the last 6 months.

Exclusion Criteria:

  • 1. History of systemic diseases affecting periodontium (e.g., uncontrolled diabetes, autoimmune diseases, osteoporosis).

    2. Current or past diagnosis of Alzheimer's disease or other neurodegenerative disorders.

    3. Use of medications affecting periodontal status (e.g., immunosuppressants, long-term corticosteroids, anticonvulsants).

    4. Antibiotic or anti-inflammatory therapy within the past 3 months. 5. Current smokers or history of smoking in the past year.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
control group
periodontally healthy participants
study group
periodontitis stage 3 and 4

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The concentration of oxLDL in GCF
Time Frame: at baseline (day1)
The concentration of oxLDL in GCF, measured in pg/mL, in geriatric patients with Stage III/IV periodontitis compared to periodontally healthy geriatric individuals.
at baseline (day1)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

shaimaa hamdy

Investigators

  • Study Chair: shaimaa Hamdy, lecturer, lecturer of periodontology Nahda University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 15, 2025

Primary Completion (Estimated)

September 15, 2025

Study Completion (Estimated)

September 15, 2025

Study Registration Dates

First Submitted

August 19, 2025

First Submitted That Met QC Criteria

September 2, 2025

First Posted (Estimated)

September 5, 2025

Study Record Updates

Last Update Posted (Estimated)

September 5, 2025

Last Update Submitted That Met QC Criteria

September 2, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GCF+ advanced periodontitis
  • committee 1166 (Other Identifier: ethical committee faculty of dentistry minia university)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

After completion of the study and complete publication, I will share all data

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Periodontal Diseases

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe